JP2011527984A - 虚血性又は炎症性の心疾患及び心臓血管疾患の予防と治療のためのフラボノイド化合物の使用 - Google Patents

虚血性又は炎症性の心疾患及び心臓血管疾患の予防と治療のためのフラボノイド化合物の使用 Download PDF

Info

Publication number
JP2011527984A
JP2011527984A JP2010549125A JP2010549125A JP2011527984A JP 2011527984 A JP2011527984 A JP 2011527984A JP 2010549125 A JP2010549125 A JP 2010549125A JP 2010549125 A JP2010549125 A JP 2010549125A JP 2011527984 A JP2011527984 A JP 2011527984A
Authority
JP
Japan
Prior art keywords
glucuronide
quercetin
kaempferol
glucoside
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010549125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527984A5 (enExample
Inventor
アンケ エシュペレシュター
シュテファン ネーズ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2011527984A publication Critical patent/JP2011527984A/ja
Publication of JP2011527984A5 publication Critical patent/JP2011527984A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2010549125A 2008-03-06 2009-03-03 虚血性又は炎症性の心疾患及び心臓血管疾患の予防と治療のためのフラボノイド化合物の使用 Pending JP2011527984A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008012909.7 2008-03-06
DE102008012909A DE102008012909A1 (de) 2008-03-06 2008-03-06 Verwendung von Flavonoidverbindungen für die Prophylaxe und Therapie ischämischer oder entzündlicher Herz- und Kreislauferkrankungen
PCT/EP2009/052502 WO2009109573A1 (de) 2008-03-06 2009-03-03 Verwendung von flavonoidverbindungen für die propyhylaxe und therapie ischämischer oder entzündlicher herz- und kreislauferkrankungen

Publications (2)

Publication Number Publication Date
JP2011527984A true JP2011527984A (ja) 2011-11-10
JP2011527984A5 JP2011527984A5 (enExample) 2012-04-26

Family

ID=40600026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549125A Pending JP2011527984A (ja) 2008-03-06 2009-03-03 虚血性又は炎症性の心疾患及び心臓血管疾患の予防と治療のためのフラボノイド化合物の使用

Country Status (6)

Country Link
US (2) US20110053874A1 (enExample)
EP (1) EP2268277A1 (enExample)
JP (1) JP2011527984A (enExample)
CA (1) CA2717012A1 (enExample)
DE (1) DE102008012909A1 (enExample)
WO (1) WO2009109573A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2195000B1 (de) * 2007-08-31 2019-09-25 Sanofi-Aventis Deutschland GmbH Sprühfähige zusammensetzung enthaltend extrakt aus rotem weinlaub
DE102008012908A1 (de) * 2008-03-06 2009-09-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methode zum anti-inflammatorischen und anti-ödematösen Schutz von explantiertem biologischen Material bis zu seiner Transplantation in Patienten
AU2013330222B2 (en) 2012-10-11 2016-05-12 Armaron Bio Pty Ltd Novel flavonoid compounds and uses thereof
CN113398114B (zh) * 2021-05-28 2022-11-01 浙江大学智能创新药物研究院 3,7,8,4′-四羟基黄酮在制备抗心血管疾病药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534285A (ja) * 2000-05-25 2003-11-18 ファルマトン ソシエテ アノニム 細胞保護を改善する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1190200C (zh) * 1998-10-29 2005-02-23 默克专利股份有限公司 包括生物黄酮醇类的混合物的组合物
JP2001122791A (ja) * 1999-10-20 2001-05-08 Boehringer Ingelheim Internatl Gmbh 下肢の慢性静脈不全の軽減および予防のための赤色ブドウ樹葉の水性抽出物よりなる食事補強剤
CN1197567C (zh) * 2002-10-21 2005-04-20 中国人民解放军第二军医大学 山奈酚衍生物用于制备防治脑血管疾病药物的用途
JP4989071B2 (ja) 2002-12-31 2012-08-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 赤ブドウ葉抽出物を含むフィルムコート錠

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534285A (ja) * 2000-05-25 2003-11-18 ファルマトン ソシエテ アノニム 細胞保護を改善する方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5012007453; ＥＳＰＥＲＥＳＴＥＲ　ＡＮＫＥ: 'ＱＵＥＲＣＥＴＩＮ-ＧＬＵＣＵＲＯＮＩＤＥ　（ＱＧ）　ＰＲＥＶＥＮＴＳ　ＭＩＣＲＯＣＩＲＣＵＬＡＴＯＲＹ　ＣＯＭＰＬＩＣＡＴＩＯＮＳ　ＡＣＵＴＥＬＹ　ＣＡＵＳＥＤ　以下備考' ＣＩＲＣＵＬＡＴＩＯＮ Ｖ１１０　Ｎ１７　ＳＵＰＰＬ．Ｓ, 200410, Ｐ１２６ *
JPN5012007454; ＦＡＮＴＩＮＥＬＬＩ　ＪＵＬＩＡＮＡ　Ｃ: 'ＣＡＲＤＩＯＰＲＯＴＥＣＴＩＶＥ　ＥＦＦＥＣＴＳ　ＯＦ　Ａ　ＮＯＮ-ＡＬＣＯＨＯＬＩＣ　ＥＸＴＲＡＣＴ　ＯＦ　ＲＥＤ　ＷＩＮＥ　ＤＵＲＩＮＧ　ＩＳＣＨＡＥＭＩＡ　以下備考' ＣＬＩＮＩＣＡＬ　ＡＮＤ　ＥＸＰＥＲＩＭＥＮＴＡＬ　ＰＨＡＲＭＡＣＯＬＯＧＹ　ＡＮＤ　ＰＨＹＳＩＯＬＯＧＹ Ｖ３４　Ｎ３, 200703, Ｐ１６６-１６９ *
JPN5012007456; ＫＩＥＳＥＷＥＴＴＥＲ　Ｈ: 'ＥＦＦＩＣＡＣＹ　ＯＦ　ＯＲＡＬＬＹ　ＡＤＭＩＮＩＳＴＥＲＥＤ　ＥＸＴＲＡＣＴ　ＯＦ　ＲＥＤ　ＶＩＮＥ　ＬＥＡＦ　ＡＳ　１９５　（ＦＯＬＩＡ　ＶＩＴＩＳ　ＶＩＮＩＦＥＲＡＥ）　以下備考' ＡＲＺＮＥＩＭＩＴＴＥＬ　ＦＯＲＳＣＨＵＮＧ／ＤＲＵＧ　ＲＥＳＥＡＲＣＨ Ｖ５０　Ｎ２, 20000101, Ｐ１０９-１１７, ＥＣＶ　ＥＤＩＴＩＯ　ＣＡＮＴＯＲ　ＶＥＲＬＡＧ *
JPN6010027017; ＬＡＲＤＯＳ　Ａ　ｅｔ　ａｌ: '薬用ハ-ブの機能性とその利用について　ＩＩＩ　赤ブドウの葉（Ｒｅｄ　Ｖｉｎｅ　Ｌｅａｆ）' 食品と開発 ２００１，Ｖｏｌ．３６，Ｎｏ．３, Ｐａｇｅ．５０-５３ *

Also Published As

Publication number Publication date
WO2009109573A1 (de) 2009-09-11
EP2268277A1 (de) 2011-01-05
DE102008012909A1 (de) 2009-09-10
US20130109641A1 (en) 2013-05-02
CA2717012A1 (en) 2009-09-11
US20110053874A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
JP6936932B2 (ja) フラボノイド組成物及び使用方法
Abreu et al. Vaccinium (Ericaceae): Ethnobotany and pharmacological potentials.
ES2323815T3 (es) Formulaciones que contienen extractos de cynara scolymus y de phaseolus vulgaris que son utiles para el tratamiento de la obesidad.
Lockyer et al. Olive leaf phenolics and cardiovascular risk reduction: physiological effects and mechanisms of action
Ku et al. Garlic and its active metabolite allicin produce endothelium-and nitric oxide-dependent relaxation in rat pulmonary arteries.
Al-Waili Intravenous and intrapulmonary administration of honey solution to healthy sheep: effects on blood sugar, renal and liver function tests, bone marrow function, lipid profile, and carbon tetrachloride-induced liver injury
TR201804828A2 (tr) Bi̇tki̇ ekstraktlari i̇çeren formülasyonlar
Adeeyo et al. Antihyperglycemic effects of aqueous leaf extracts of mistletoe and Moringa oleifera in streptozotocin-induced diabetes Wistar rats.
Arya et al. Bioactive compounds and health benefits of jamun (Syzygium cumini)
RU2216329C2 (ru) Средство от простудных заболеваний
JP2011527984A (ja) 虚血性又は炎症性の心疾患及び心臓血管疾患の予防と治療のためのフラボノイド化合物の使用
CN107073026B (zh) 用于治疗高血糖疾病的生物活性物质组合
ES2342018T3 (es) Metodo de tratamiento de afecciones inflamatorias usando extractos de maracuya.
Kick et al. Effects of a cantaloupe melon extract/wheat gliadin biopolymer during aortic cross-clamping
Yang et al. Toona sinensis leaf aqueous extract displays activity against sepsis in both in vitro and in vivo models
Makowczynska et al. Antioxidant activity of tissue culture-raised Ballota nigra L. plants grown ex vitro
DK2120924T3 (en) Anti-diabetic honey bush-extract
KR20140077483A (ko) 갯방풍 추출물을 포함하는 허혈성 뇌혈관 질환 예방 또는 개선용 조성물
KR102253137B1 (ko) 진세노사이드 Re를 포함하는 거저리 유충 추출물을 유효성분으로 포함하는 항염증용 조성물
KR100665504B1 (ko) 눈개승마 추출물을 포함하는 허혈성 질환 및 퇴행성뇌질환의 예방 및 치료를 위한 조성물
KR20140137288A (ko) 고량강 추출물을 함유하는 숙취해소 및 간 질환의 치료 및 예방용 조성물
Jankyova et al. The evaluation of efficacy of pycnogenol® fractions on endothelial dysfunction
WO2021244547A1 (zh) 天然化合物及其衍生物在治疗动脉病变中的应用
JP2006036787A (ja) キサンチンオキシダーゼ阻害剤
KR100417244B1 (ko) 분죽 추출물을 함유하는 혈액순환개선용 약학조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140106